BR112012011947B8 - forma de sal de um conjugado de fármaco-polímero com múltiplos braços - Google Patents

forma de sal de um conjugado de fármaco-polímero com múltiplos braços

Info

Publication number
BR112012011947B8
BR112012011947B8 BR112012011947A BR112012011947A BR112012011947B8 BR 112012011947 B8 BR112012011947 B8 BR 112012011947B8 BR 112012011947 A BR112012011947 A BR 112012011947A BR 112012011947 A BR112012011947 A BR 112012011947A BR 112012011947 B8 BR112012011947 B8 BR 112012011947B8
Authority
BR
Brazil
Prior art keywords
armed
salt form
polymer conjugate
drug
conjugate
Prior art date
Application number
BR112012011947A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012011947A2 (pt
BR112012011947B1 (pt
Inventor
O Chong Anthony
Kozlowski Antoni
V Joshi Bhalchandra
Bray Brian
Swallow David
Lavaty Greg
Spence Patrick
Tipnis Sachin
Mcmanus Samuel
Lee Seoju
Nie Shaoyong
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of BR112012011947A2 publication Critical patent/BR112012011947A2/pt
Publication of BR112012011947B1 publication Critical patent/BR112012011947B1/pt
Publication of BR112012011947B8 publication Critical patent/BR112012011947B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • C07C51/412Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16Halogenated acetic acids
    • C07C53/18Halogenated acetic acids containing fluorine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48Polymers modified by chemical after-treatment
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Support Of Aerials (AREA)
  • Cephalosporin Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112012011947A 2009-11-18 2010-11-18 forma de sal de um conjugado de fármaco-polímero com múltiplos braços BR112012011947B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26246309P 2009-11-18 2009-11-18
US61/262,463 2009-11-18
US29007209P 2009-12-24 2009-12-24
US61/290,072 2009-12-24
PCT/US2010/057292 WO2011063158A1 (en) 2009-11-18 2010-11-18 Salt form of a multi-arm polymer-drug conjugate

Publications (3)

Publication Number Publication Date
BR112012011947A2 BR112012011947A2 (pt) 2018-09-11
BR112012011947B1 BR112012011947B1 (pt) 2021-05-18
BR112012011947B8 true BR112012011947B8 (pt) 2021-05-25

Family

ID=43639124

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012011947A BR112012011947B8 (pt) 2009-11-18 2010-11-18 forma de sal de um conjugado de fármaco-polímero com múltiplos braços
BR112012011943-5A BR112012011943A2 (pt) 2009-11-18 2010-11-18 formas de sais de ácidos de conjugados de polímero-fármaco e métodos de alcoxilação

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112012011943-5A BR112012011943A2 (pt) 2009-11-18 2010-11-18 formas de sais de ácidos de conjugados de polímero-fármaco e métodos de alcoxilação

Country Status (24)

Country Link
US (5) US9226969B2 (enExample)
EP (3) EP3498754A1 (enExample)
JP (3) JP5901073B2 (enExample)
KR (2) KR101790804B1 (enExample)
CN (2) CN102711837B (enExample)
AU (1) AU2010321882B2 (enExample)
BR (2) BR112012011947B8 (enExample)
CA (3) CA3063465C (enExample)
CY (1) CY1121700T1 (enExample)
DK (1) DK2501413T3 (enExample)
EA (2) EA023503B1 (enExample)
ES (2) ES2623677T3 (enExample)
HR (1) HRP20191138T1 (enExample)
HU (1) HUE043689T2 (enExample)
IL (2) IL219865A (enExample)
LT (1) LT2501413T (enExample)
ME (1) ME03396B (enExample)
MX (2) MX338134B (enExample)
PL (1) PL2501413T3 (enExample)
PT (1) PT2501413T (enExample)
RS (1) RS58901B1 (enExample)
SI (1) SI2501413T1 (enExample)
SM (1) SMT201900294T1 (enExample)
WO (2) WO2011063156A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2907524A1 (en) 2007-05-25 2015-08-19 RB Pharmaceuticals Limited Sustained delivery formulations of risperidone compounds
AU2010321882B2 (en) 2009-11-18 2016-01-14 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US20140378404A1 (en) * 2011-10-25 2014-12-25 Nektar Therapeutics Treatment of Patients Suffering from Cancer
SI2841447T1 (sl) * 2012-04-26 2018-10-30 Amylex Pharmaceuticals, Inc. Novi sestavek za zunajtelesno redukcijo beta-amiloidov in postopek za njega izdelavo
JP6300460B2 (ja) * 2012-07-20 2018-03-28 キヤノン株式会社 化合物、および前記化合物を有する光音響イメージング用造影剤
WO2014036566A1 (en) * 2012-08-31 2014-03-06 Virginia Commonwealth University Clickable polyoxetane carrier for drug delivery
MX366911B (es) 2012-11-28 2019-07-30 Nektar Therapeutics Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de topoisomerasa i de acción prolongada.
US9493766B2 (en) * 2013-02-04 2016-11-15 Corning Incorporated PCR reaction cleanup buffers
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2014194289A1 (en) 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
CN104225611B (zh) * 2013-06-18 2017-06-30 天津键凯科技有限公司 达沙替尼与非线性构型聚乙二醇的结合物
JP7097667B2 (ja) * 2013-09-27 2022-07-08 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体
SG11201602258WA (en) * 2013-10-04 2016-04-28 Prolynx Llc Slow-release conjugates of sn-38
JP5721806B2 (ja) * 2013-10-04 2015-05-20 Delta−Fly Pharma株式会社 副作用のない抗癌剤
KR102501566B1 (ko) 2014-01-14 2023-02-17 넥타르 테라퓨틱스 병용 기반 치료 방법
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
RU2697551C2 (ru) * 2014-12-04 2019-08-15 Дельта-Флай Фарма, Инк. Новые производные peg
US10548984B2 (en) * 2015-02-04 2020-02-04 United Arab Emirates University RVG Derived peptides
WO2017027843A1 (en) 2015-08-12 2017-02-16 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
CN107019803B (zh) * 2016-01-29 2020-09-15 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药(苏州)股份有限公司 多臂的聚合靶向抗癌偶联物
CN107469089B (zh) 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
AU2018207283C1 (en) 2017-01-10 2024-05-02 Nektar Therapeutics Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
WO2018143122A1 (ja) * 2017-02-02 2018-08-09 アルプス電気株式会社 平衡式電流センサ
KR102279429B1 (ko) 2017-04-21 2021-07-20 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. 멀티 암 표적 항암 콘쥬게이트
CN108727584B (zh) * 2017-04-21 2021-01-05 博瑞生物医药(苏州)股份有限公司 抗癌偶联物
WO2019046452A1 (en) * 2017-09-01 2019-03-07 Arizona Board Of Regents On Behalf Of Arizona State University THIXOTROPIC BIOCOMPATIBLE GEL FOR OBSERVATION OF LIVING CELLS IN COMPUTER-ASSISTED TOMOGRAPHY ON CELLS
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス, インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
WO2019096096A1 (zh) * 2017-11-14 2019-05-23 博瑞生物医药(苏州)股份有限公司 多臂靶向偶联物
CN107854693B (zh) * 2017-11-14 2020-07-14 高瑞耀业(北京)科技有限公司 整合素受体靶向的抗癌偶联物
CN109776787B (zh) * 2017-11-14 2021-08-03 博瑞生物医药(苏州)股份有限公司 多臂靶向偶联物
CN111526891B (zh) * 2017-12-27 2023-10-20 三洋化成工业株式会社 药品原料药用原料或药品用添加物和使用了它们的药品原料药或药品
US11730836B2 (en) * 2018-01-12 2023-08-22 Prolynx Llc Synergistic cancer treatment
US11458094B2 (en) * 2018-01-31 2022-10-04 Regents Of The University Of Minnesota Compositions and methods for treating pulmonary edema or lung inflammation
CN110256533B (zh) * 2018-03-12 2022-05-10 博瑞生物医药(苏州)股份有限公司 一种高纯度的多臂抗癌偶联物的提取方法
CN110577552A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-5,6-双脱氢去甲斑蝥素结合物及其应用
JP7546552B2 (ja) 2018-09-17 2024-09-06 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア ポリマーベースの高分子プロドラッグ
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
US20220305025A1 (en) * 2019-08-15 2022-09-29 The Research Foundation For The State University Of New York Phosphatidylserine binding molecules block immune suppression of tumor associated exosomes
CN114705801B (zh) * 2022-01-24 2024-02-27 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) 一种利福霉素类药物中亚硝酸根离子的测定方法
WO2025053315A1 (ko) * 2023-09-08 2025-03-13 파로스젠 주식회사 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1222261B (de) * 1963-04-20 1966-08-04 Bayer Ag Verfahren zur Herstellung von Polyaethern durch Polymerisation von Alkylenoxyden
GB1157653A (en) * 1966-06-24 1969-07-09 Bp Chem Int Ltd Improvements in or relating to Synthetic Lubricants
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5399728A (en) * 1993-04-05 1995-03-21 Arco Chemical Technology, L.P. Process for the preparation of highly esterified alkoxylated polyol compositions
GB9704126D0 (en) * 1997-02-27 1997-04-16 Ici Plc Surfactants
DE19817676A1 (de) * 1998-04-21 1999-10-28 Bayer Ag Verfahren zur aufarbeitungsfreien Herstellung langkettiger Polyetherpolyole
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
DE19937114C2 (de) * 1999-08-06 2003-06-18 Bayer Ag Verfahren zur Herstellung von Polyetherpolyolen
US6762325B2 (en) 2001-05-16 2004-07-13 Nippon Shokubai Co., Ltd. Method for production of alkoxylated compound
SE523934C2 (sv) * 2001-09-24 2004-06-01 Perstorp Specialty Chem Ab Förfarande för av alkoxylering av di-, tri och polyalkoholer
US6608076B1 (en) * 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
US8357377B2 (en) * 2002-10-09 2013-01-22 Suzie Hwang Pun Cyclodextrin-based materials, compositions and uses related thereto
US20050043215A1 (en) * 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
NZ541374A (en) * 2003-05-23 2008-09-26 Nektar Therapeutics Al Corp PEG derivatives having an amidocarbonate linkage
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
LT1675622T (lt) * 2003-09-17 2017-09-11 Nektar Therapeutics Daugiašakio polimero provaistai
CN101132812A (zh) * 2004-03-15 2008-02-27 阿拉巴马耐科塔医药公司 Hiv进入抑制剂的聚合物基组合物和结合物
ES2534853T3 (es) * 2004-10-01 2015-04-29 Kabushiki Kaisha Yakult Honsha Sal de adición de ácido de irinotecán
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
ATE524509T1 (de) 2005-07-18 2011-09-15 Nektar Therapeutics Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
IE20060565A1 (en) * 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
JP5105166B2 (ja) * 2007-12-19 2012-12-19 公益財団法人野口研究所 ポリエーテルの製造方法
AU2010321882B2 (en) 2009-11-18 2016-01-14 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate

Also Published As

Publication number Publication date
MX2012005795A (es) 2012-09-07
EA201290342A1 (ru) 2012-10-30
PL2501413T3 (pl) 2019-09-30
AU2010321880A1 (en) 2012-06-07
KR101779229B1 (ko) 2017-09-18
EA024533B1 (ru) 2016-09-30
CA2780779A1 (en) 2011-05-26
EP3498754A1 (en) 2019-06-19
JP5901073B2 (ja) 2016-04-06
CN102711837A (zh) 2012-10-03
SI2501413T1 (sl) 2019-06-28
BR112012011947A2 (pt) 2018-09-11
US11834553B2 (en) 2023-12-05
ES2723026T3 (es) 2019-08-21
MX2012005794A (es) 2012-10-09
US9226969B2 (en) 2016-01-05
US20130231359A1 (en) 2013-09-05
CA2780779C (en) 2020-02-04
BR112012011943A2 (pt) 2018-09-11
WO2011063158A1 (en) 2011-05-26
PT2501413T (pt) 2019-07-10
KR20120101070A (ko) 2012-09-12
JP2013511540A (ja) 2013-04-04
EA201200751A8 (ru) 2014-07-30
EP2501412B1 (en) 2017-03-29
KR101790804B1 (ko) 2017-10-26
LT2501413T (lt) 2019-05-10
WO2011063156A2 (en) 2011-05-26
CN102711836B (zh) 2017-05-10
EA023503B1 (ru) 2016-06-30
CA2780645A1 (en) 2011-05-26
DK2501413T3 (da) 2019-06-11
US20160200867A1 (en) 2016-07-14
RS58901B1 (sr) 2019-08-30
CA3063465C (en) 2023-01-03
EP2501412A1 (en) 2012-09-26
KR20120104243A (ko) 2012-09-20
JP2013511539A (ja) 2013-04-04
WO2011063156A3 (en) 2011-08-25
EP2501413B1 (en) 2019-03-27
CN102711836A (zh) 2012-10-03
MX338134B (es) 2016-04-01
IL219866A (en) 2017-03-30
EA201290342A8 (ru) 2014-07-30
AU2010321882B2 (en) 2016-01-14
CA3063465A1 (en) 2011-05-26
US20210024693A1 (en) 2021-01-28
CA2780645C (en) 2018-01-16
HUE043689T2 (hu) 2019-09-30
JP5951496B2 (ja) 2016-07-13
SMT201900294T1 (it) 2019-07-11
IL219865A0 (en) 2012-07-31
CY1121700T1 (el) 2020-07-31
EP2501413A2 (en) 2012-09-26
ME03396B (me) 2020-01-20
US9320808B2 (en) 2016-04-26
US20130143909A1 (en) 2013-06-06
US20150105519A1 (en) 2015-04-16
IL219866A0 (en) 2012-07-31
EA201200751A1 (ru) 2013-03-29
HRP20191138T1 (hr) 2019-09-20
AU2010321882A1 (en) 2012-05-31
IL219865A (en) 2017-03-30
MX337393B (es) 2016-03-02
ES2623677T3 (es) 2017-07-12
CN102711837B (zh) 2016-10-19
BR112012011947B1 (pt) 2021-05-18
JP2016006127A (ja) 2016-01-14

Similar Documents

Publication Publication Date Title
BR112012011947B8 (pt) forma de sal de um conjugado de fármaco-polímero com múltiplos braços
AU335655S (en) A bowl
AU335703S (en) Flood light
AU310935S (en) Earphones
AU319298S (en) Headphone
AU332590S (en) A chair
AU316104S (en) Therapeutic footwear with round cushion
AU332794S (en) A chair
AU333448S (en) Light fixture
AU333926S (en) Light fixture
AU322350S (en) Vial with projection
AU320230S (en) Drug delivery patch
AU335448S (en) Chair
AU312755S (en) Bait station
AU328360S (en) Supporting base
CA146804S (en) Diaper
AU331987S (en) Downlights
CA121447S (en) Ring
CA137267S (en) Lighting fixture
CA137134S (en) Lighting fixture
AU318474S (en) Ring
CA133852S (en) Lighting fixture
CA133829S (en) Lighting fixture
CA133851S (en) Lighting fixture
AU334587S (en) A swaddling

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 47/48 , A61P 35/00

Ipc: A61K 47/60 (2017.01), C08G 65/329 (2006.01), C08G

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF